Your browser does not allow saving data (e.g. private mode): bookmarks will be lost when the tab closes.
Search PubMed
Keywords, author, journal, years — results from PubMed, abstracts with Russian translation, bookmarks in your browser.
Found: 4 942
Page 353 of 495-
CCR7 immune cell receptor expression in inflammatory breast cancer.
Inflammatory breast cancer (IBC) is characterized by congestion of dermal lymphovascular spaces by tumor emboli. We characterized expression of CCR7, a lymphocyte homing chemokine receptor, in IBC cell lines and patient tissues. CCR7 gene expression was quantified using World IBC Consortium Database and correlated with protein expression in cell lines and IBC mastectomy samples post-neoadjuvant therapy. CCR7 expression on tissue microarray (TMA) was scored by staining pattern (complete vs. incomplete membranous), percent tumor stained, and staining intensity. CCR7 was highly expressed in IBC cell lines and a previously validated preclinical mouse model. Among 137 IBC and 252 non-IBC patient samples, CCR7 gene expression was significantly higher in IBC compared to non-IBC (p = 0.0007). Within IBC samples, gene expression was higher in HER2+ (p = 0.0002), basal (p = 0.0161), and ER- IBC patients (p = 0.010). Of the 24 IBC TMAs, almost all were CCR7 positive (23, 95.8%), with 15 (62.5%) demonstrating completely membranous expression. CCR7 is highly expressed in IBC cell lines and patient tumor samples, with preferential expression in HER2-positive and basal-like IBC subtypes. Given its high prevalence, CCR7 may serve as a potential target for antibody-based drug design in future IBC studies.
-
Effects of HOX family regulator-mediated modification patterns and immunity characteristics on tumor-associated cell type in endometrial cancer.
Endometrial cancer (UCEC) is one of three major malignant tumors in women. The HOX gene regulates tumor development. However, the potential roles of HOX in the expression mechanism of multiple cell types and in the development and progression of tumor microenvironment (TME) cell infiltration in UCEC remain unknown. In this study, we utilized both the The Cancer Genome Atlas (TCGA) database and International Cancer Genome Consortium (ICGC) database to analyze transcriptome data of 529 patients with UCEC based on 39 HOX genes, combing clinical information, we discovered HOX gene were a pivotal factor in the development and progression of UCEC and in the formation of TME diversity and complexity. Here, a new scoring system was developed to quantify individual HOX patterns in UCEC. Our study found that patients in the low HOX score group had abundant anti-tumor immune cell infiltration, good tumor differentiation, and better prognoses. In contrast, a high HOX score was associated with blockade of immune checkpoints, which enhances the response to immunotherapy. The Real-Time quantitative PCR (RT-qPCR) and Immunohistochemistry (IHC) exhibited a higher expression of the HOX gene in the tumor patients. We revealed that the significant upregulation of the HOX gene in the epithelial cells can activate signaling pathway associated with tumour invasion and metastasis through single-cell RNA sequencing (scRNA-seq), such as nucleotide metabolic proce and so on. Finally, a risk prognostic model established by the positive relationship between HOX scores and cancer-associated fibroblasts (CAFs) can predict the prognosis of individual patients by scRNA-seq and transcriptome data sets. In sum, HOX gene may serve as a potential biomarker for the diagnosis and prediction of UCEC and to develop more effective therapeutic strategies.
-
Single-cell RNA sequencing and multi-omics analysis of prognosis-related staging in papillary thyroid cancer.
BACKGROUND: Papillary thyroid cancer (PTC) is the most common thyroid cancer, but current molecular features inadequately stratify its risk. Whether distinct underlying mechanisms can further classify PTC and improve prognostic precision remains unclear. METHODS: We integrated single-cell RNA sequencing data (158,577 cells from 11 PTC patients; GEO: GSE184362) with bulk-RNA sequencing data from The Cancer Genome Atlas Thyroid Carcinoma (TCGA-THCA) cohort (501 patients). Multi-omics analyses were employed to elucidate PTC heterogeneity, identify malignant cell differentiation and prognosis-related genes (MCD&PRGs), and construct a novel molecular classification, the Oncogenic Signature Of Papillary Thyroid Carcinoma Classification (OSPTCC). A prognostic risk score was developed, and the classification's prognostic relevance was further explored in an independent institutional cohort using qRT-PCR. RESULTS: Single-cell analysis revealed three malignant cell differentiation states (PTC1-3) and a 34-gene signature (MCD&PRGs). This formed the basis of our Oncogenic Signature Of Papillary Thyroid Carcinoma Classification (OSPTCC), defining three subtypes: Inflammation-associated (IPTCC), BRAF/autophagy-related (BAPTCC), and lipid metabolism-related (LPTCC). These subtypes showed distinct molecular profiles and significantly different progression-free survival (IPTCC poorest, P = 0.044). A 7-gene risk score derived from MCD&PRGs independently predicted prognosis (multivariate HR = 21.511, P < 0.001). qRT-PCR validation in an independent cohort (n = 48) using key markers (DEPTOR, APOE, APOC1) confirmed that OSPTCC-based risk stratification correlated with adverse clinical features, including higher recurrence rates in the high-risk group (P = 0.007). CONCLUSIONS: This study introduces OSPTCC, a prognostically significant molecular classification for PTC based on tumor cell differentiation states. The identified subtypes, characterized by distinct biological mechanisms, provide deeper insights into PTC's molecular pathology and offer a framework for improved risk stratification and potential precision therapies.
-
A single-cell atlas of bladder cancer unveils dynamic cellular composition and endothelial functional shifts during progression.
PURPOSE: Bladder cancer (BC) is characterized by high heterogeneity, with non-muscle-invasive (NMIBC) and muscle-invasive (MIBC) stages differing significantly in clinical behavior and outcomes. The transition from NMIBC to MIBC involves extensive tumor microenvironment (TME) remodeling, particularly in endothelial cells (ECs), which drive angiogenesis and modulate immune and extracellular matrix (ECM) interactions. However, the precise roles of ECs in this progression remain poorly defined. METHODS: Public single-cell RNA sequencing (scRNA-seq) datasets from 47 BC patients were analyzed to characterize endothelial cell heterogeneity and functional states across NMIBC and MIBC. Computational tools such as CellChat were applied to reconstruct cell-cell communication networks, focusing on pathways related to angiogenesis, immune crosstalk, and ECM remodeling. RESULTS: Twelve major cell types were identified, with endothelial cells exhibiting distinct transcriptional profiles between NMIBC and MIBC. NMIBC-associated ECs promoted adhesion and migration through HMGB1 and CXCL12 signaling. In contrast, MIBC was enriched in an ADAM10+ endothelial subset associated with vascular remodeling and activation of Wnt signaling via CTNNB1. Key ligand-receptor interactions highlighted the dynamic roles of ECs in TME modulation during BC progression. CONCLUSIONS: This study reveals stage-specific endothelial cell phenotypes and signaling networks in BC. The identification of an MIBC-specific ADAM10+ endothelial subset underscores its potential role in driving tumor progression and highlights opportunities for stage-adapted vascular-targeted therapies. These findings advance our understanding of BC pathogenesis and provide the foundation for novel therapeutic strategies.
-
Placenta accreta spectrum disorder at single-cell resolution: a loss of boundary limits in the decidua and endothelium.
BACKGROUND: Placenta accreta spectrum disorders are associated with severe maternal morbidity and mortality. Placenta accreta spectrum disorders involve excessive adherence of the placenta preventing separation at birth. Traditionally, this condition has been attributed to excessive trophoblast invasion; however, an alternative view is a fundamental defect in decidual biology. OBJECTIVE: This study aimed to gain insights into the understanding of placenta accreta spectrum disorder by using single-cell and spatially resolved transcriptomics to characterize cellular heterogeneity at the maternal-fetal interface in placenta accreta spectrum disorders. STUDY DESIGN: To assess cellular heterogeneity and the function of cell types, single-cell RNA sequencing and spatially resolved transcriptomics were used. A total of 12 placentas were included, 6 placentas with placenta accreta spectrum disorder and 6 controls. For each placenta with placenta accreta spectrum disorder, multiple biopsies were taken at the following sites: placenta accreta spectrum adherent and nonadherent sites in the same placenta. Of note, 2 platforms were used to generate libraries: the 10× Chromium and NanoString GeoMX Digital Spatial Profiler for single-cell and spatially resolved transcriptomes, respectively. Differential gene expression analysis was performed using a suite of bioinformatic tools (Seurat and GeoMxTools R packages). Correction for multiple testing was performed using Clipper. In situ hybridization was performed with RNAscope, and immunohistochemistry was used to assess protein expression. RESULTS: In creating a placenta accreta cell atlas, there were dramatic difference in the transcriptional profile by site of biopsy between placenta accreta spectrum and controls. Most of the differences were noted at the site of adherence; however, differences existed within the placenta between the adherent and nonadherent site of the same placenta in placenta accreta. Among all cell types, the endothelial-stromal populations exhibited the greatest difference in gene expression, driven by changes in collagen genes, namely collagen type III alpha 1 chain (COL3A1), growth factors, epidermal growth factor-like protein 6 (EGFL6), and hepatocyte growth factor (HGF), and angiogenesis-related genes, namely delta-like noncanonical Notch ligand 1 (DLK1) and platelet endothelial cell adhesion molecule-1 (PECAM1). Intraplacental tropism (adherent versus non-adherent sites in the same placenta) was driven by differences in endothelial-stromal cells with notable differences in bone morphogenic protein 5 (BMP5) and osteopontin (SPP1) in the adherent vs nonadherent site of placenta accreta spectrum. CONCLUSION: Placenta accreta spectrum disorders were characterized at single-cell resolution to gain insight into the pathophysiology of the disease. An atlas of the placenta at single cell resolution in accreta allows for understanding in the biology of the intimate maternal and fetal interaction. The contributions of stromal and endothelial cells were demonstrated through alterations in the extracellular matrix, growth factors, and angiogenesis. Transcriptional and protein changes in the stroma of placenta accreta spectrum shift the etiologic explanation away from "invasive trophoblast" to "loss of boundary limits" in the decidua. Gene targets identified in this study may be used to refine diagnostic assays in early pregnancy, track disease progression over time, and inform therapeutic discoveries.
-
Temporal analysis of enhancers during mouse cerebellar development reveals dynamic and novel regulatory functions.
We have identified active enhancers in the mouse cerebellum at embryonic and postnatal stages which provides a view of novel enhancers active during cerebellar development. The majority of cerebellar enhancers have dynamic activity between embryonic and postnatal development. Cerebellar enhancers were enriched for neural transcription factor binding sites with temporally specific expression. Putative gene targets displayed spatially restricted expression patterns, indicating cell-type specific expression regulation. Functional analysis of target genes indicated that enhancers regulate processes spanning several developmental epochs such as specification, differentiation and maturation. We use these analyses to discover one novel regulator and one novel marker of cerebellar development: Bhlhe22 and Pax3, respectively. We identified an enrichment of de novo mutations and variants associated with autism spectrum disorder in cerebellar enhancers. Furthermore, by comparing our data with relevant brain development ENCODE histone profiles and cerebellar single-cell datasets we have been able to generalize and expand on the presented analyses, respectively. We have made the results of our analyses available online in the Developing Mouse Cerebellum Enhancer Atlas, where our dataset can be efficiently queried, curated and exported by the scientific community to facilitate future research efforts. Our study provides a valuable resource for studying the dynamics of gene expression regulation by enhancers in the developing cerebellum and delivers a rich dataset of novel gene-enhancer associations providing a basis for future in-depth studies in the cerebellum.
-
Aged brain multi-omic integration captures immunometabolic and sex variation.
Resolving the molecular basis for heterogeneous ageing in the human brain requires integrating its diverse molecular layers. Here we applied a tensor-decomposition framework to jointly analyse single-nucleus RNA-seq, DNA methylation, H3K9ac histone acetylation and proteomic data from 276 post-mortem human cortices. The analysis uncovered two dominant, multi-omic themes. First, we identified an immunometabolic axis characterised by microglial activation, suppression of PI3K-Akt-mTOR signalling and epigenetic signatures that suggest repurposing of developmental transcription factors such as BARHL1. Second, we decomposed the effect of sex into a multi-omic program linked to cellular plasticity: although driven by canonical sex-chromosome genes, this axis was epigenetically enriched for pathways regulating stem-cell pluripotency and exhibited a female-biased shift toward precursor-like states in the oligodendrocyte lineage. Together, these findings deliver a high-resolution atlas of glial ageing and demonstrate that broad risk factors manifest as complex, cell-specific vulnerabilities; an insight critical for the development of targeted therapeutic strategies.
-
Single-cell analysis reveals crosstalk between TREM1-positive myeloid cells and cancer-associated fibroblasts in colorectal cancer progression.
BACKGROUND: The limited efficacy of immunotherapy in colorectal cancer (CRC) underscores the need to better define immunosuppressive mechanisms within the tumor microenvironment (TME). We applied single-cell RNA sequencing (scRNA-seq) to characterize stromal-immune interactions shaping the CRC TME. METHODS: Paired tumor and adjacent normal mucosa samples from eight patients with CRC were analyzed by scRNA-seq. Integrated bioinformatic approaches, including trajectory inference, transcriptional regulon analysis, and cell-cell communication modeling, were used to define cellular differentiation and intercellular signaling. Key findings were validated using The Cancer Genome Atlas datasets, multiplex immunofluorescence staining, and in vitro functional assays. RESULTS: Trajectory analysis demonstrated a progressive increase in triggering receptor expressed on myeloid cells 1 (TREM1) expression during tumor-associated myeloid differentiation. TREM1-positive myeloid cells exhibited enriched M2-like signatures and were preferentially associated with consensus molecular subtype 4 tumors, characterized by stromal activation and poor clinical outcomes. Stromal profiling identified an α-smooth muscle actin (ACTA2)-positive population associated with CRC progression. Spatial analyses revealed close localization of TREM1-positive myeloid cells and ACTA2-positive cancer-associated fibroblasts (CAFs) in tumor tissues. Mechanistically, integrated bioinformatic analyses indicated that TREM1-positive myeloid cells engage CAFs primarily through secreted phosphoprotein 1 (SPP1) signaling, while CAFs reinforce immunosuppressive myeloid phenotypes via TGF-β-associated extracellular matrix pathways. Functional assays showed that TREM1 inhibition reduced SPP1 expression and attenuated M2 macrophage polarization. CONCLUSIONS: These findings identify a bidirectional interaction between TREM1-positive myeloid cells and CAFs that contributes to a profibrotic and immunosuppressive CRC microenvironment, highlighting the TREM1-SPP1 axis as a pathway of potential translational relevance.
-
Early microglial priming in Alzheimer's disease revealed by ME-seq.
Epigenetic modifications, particularly DNA methylation, change dynamically with aging and are implicated in Alzheimer's Disease (AD), yet how methylation interfaces with transcriptional and chromatin regulation at single-cell resolution remains poorly understood. Progress has been limited by a lack of scalable technologies capable of jointly profiling these regulatory layers. Here, we present ME-seq, a highly scalable technologies capable of simultaneously profiling DNA methylation, gene expression, and chromatin accessibility, while achieving a 100-fold reduction in cost. We generated over 400,000 single-nucleus trimodal profiles from the aging and AD mouse brain across ages, producing the first such atlas of neurodegeneration. We found AD progression triggers pronounced, disease-specific shifts in cellular composition, characterized by accelerated epigenetic aging and the expansion of disease-associated microglia (DAM). Integrative analyses, including aging clocks, revealed that DNA methylation acts as an early priming layer preceding transcriptional activation with IRF1 identified as a methylation-sensitive transcription factor serving as a gatekeeper for DAM activation. Our results establish ME-seq as a transformative tool for large-scale epigenomic dissection, revealing DNA methylation as a primary coordinator of cell-state transitions in the aging brain.
-
Gene regulatory programs of cognitive resilience and pathogenesis in Alzheimer's disease.
INTRODUCTION: Cognitive resilience in Alzheimer's disease (AD), wherein individuals maintain cognition despite substantial neuropathology, implies protective regulatory programs that remain poorly characterized. METHODS: We constructed a cell-type-resolved gene regulatory network atlas from 1.7 million nuclei across 687 individuals spanning 26 cell types in the dorsolateral prefrontal cortex, classified as Control, Resilient, or AD dementia. RESULTS: Analysis of 223 transcription factor regulons reveals a three-state regulatory framework: homeostatic erosion of IRF8/STAT1 interferon programs (State I), compensatory NF-κB suppression via BCL6 that distinguishes resilient from demented individuals (State II), and pathogenic FLI1/IKZF1 network expansion driving vascular-immune remodeling (State III). NF-κB emerges as the central hub, with BCL6-mediated repression and FLI1/RELA-driven activation constituting opposing molecular switches. DISCUSSION: Replicated across independent cohorts, these findings model resilience as an active regulatory state and nominate stage-specific therapeutic strategies: restoring homeostatic programs, prolonging compensatory suppression, and constraining inflammatory escalation.